Kymera Therapeutics (KYMR) Appoints Leigh Morgan to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
July 8, 2022 7:30 AM EDTWATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymeras Board as a senior executive accomplished in scaling global, profitable, high-performing organizations.
Leigh has distinguished herself as an expert in developing world-class organizations in a wide variety of settings, and Im thrilled to welcome her to Kymeras Board of Directors, said Nello Mainolfi, PhD, Co-Founder, President and Chief... More
